Close Menu

NEW YORK – Two months after going public, Exagen has big plans for its future in the autoimmune diagnostic arena.

With nine tests currently on the market and several more in the pipeline, the company is using its proprietary cell-bound complement activation products (CB-CAPS) technology to expand its offerings and provide more options for patients with autoimmune disorders, a market that Exagen CEO Ron Rocca estimated at $5 billion annually. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.